Press Releases Cara Therapeutics, Inc.

Equities

CARA

US1407551092

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.6843 ^USD	-2.24%		+3.52%	-7.90%

Mar. 22	Cara Therapeutics, Inc. Announces Resignation of Dr. Joana Goncalves as Chief Medical Officer, Effective April 16, 2024	CI
Mar. 06	Canaccord Genuity Adjusts Cara Therapeutics Price Target to $10 From $11, Maintains Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 02	GL
Cara Therapeutics to Host Notalgia Paresthetica Virtual KOL Event on Wednesday, March 27, 2024	Mar. 08	AQ
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024	Mar. 07	GL
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024	Mar. 07	AQ
Cara: Q4 Earnings Snapshot	Mar. 04	AQ
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results	Mar. 04	GL
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024	Feb. 12	GL
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024	Feb. 12	AQ
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026	Jan. 22	GL
Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis	Dec. 18	GL
Cara: Q3 Earnings Snapshot	Nov. 13	AQ
Cara Therapeutics Reports Third Quarter 2023 Financial Results	Nov. 13	GL
Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty	Nov. 02	GL
Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023	23-10-23	GL
Cara Therapeutics Announces Approval of KORSUVA IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients	23-09-26	AQ
Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients	23-09-25	GL
Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients	23-09-25	AQ
Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference	23-09-05	GL
Cara: Q2 Earnings Snapshot	23-08-07	AQ
Cara Therapeutics Reports Second Quarter 2023 Financial Results	23-08-07	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cara Therapeutics, Inc.

Equities

CARA

US1407551092

Press Releases

Filters